The protein plays a key role in drug resistance, a major challenge in oncology, and the new insights ... Using The Hormel Institute’s cryogenic-sample electron microscopy (cryoEM) technology ...

This study considered a sample size of 290 and the data were collected from ... Regarding the reference number, the SLESRC was not issuing reference numbers to approve ethical clearance letters during ...

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved ...

“Most people don’t want to credit samples [in that way],” says Rob Sevier, co-founder of Numero Group, which gets about three sample requests a week. To prevail in clearance ...

2025--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S ...

Based on this clearance, ALX Oncology will initiate a single-agent dose-escalation and expansion Phase 1 clinical trial for ALX2004 in mid-2025. “Clinical advancement of our first ADC and the ...

The Aurora system’s 40mm detector is stated to provide double the coverage of other hybrid systems' CT detectors.

Verastem Oncology said Wednesday that the Food and Drug Administration cleared the company's investigational new drug application for its potential treatment of certain cancers. The ...

About VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...